<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01742767</url>
  </required_header>
  <id_info>
    <org_study_id>2011-001963-37</org_study_id>
    <nct_id>NCT01742767</nct_id>
  </id_info>
  <brief_title>Cisplatinum/Pemetrexed Versus Split-dose Cisplatinum/Pemetrexed In NSCLC</brief_title>
  <acronym>PemSplitCisp</acronym>
  <official_title>Randomized Phase II Trial of Three-weekly Cisplatinum and Pemetrexed Versus Split-dose d1 and d8 Cisplatinum and Pemetrexed In Advanced and Inoperable Non-squamous Non-small-cell Lung Cancer (NSCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universität Duisburg-Essen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Universität Duisburg-Essen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cisplatinum and pemetrexed (ALIMTA®) has become an effective first-line regimen for advanced&#xD;
      and inoperable non-squamous NSCLC without somatic activating mutations of epidermal growth&#xD;
      factor receptor (EGFR). In the standard regimen the cisplatinum dose is 75 mg/m2 on day 1 of&#xD;
      a 21-day cycle. Due to the high platinum-dose patients do need a strict hyperhydration and&#xD;
      often have to be hospitalized for survey. Split-dose cisplatinum with two administrations on&#xD;
      Day 1 and 8 of a 21-day-cycle has already been administered in other platin-containing&#xD;
      chemotherapy regimens (cis/gem cis/nav cis/paclitaxel cis/docetaxel) with favourable toxicity&#xD;
      profiles and generally with an excellent patient compliance.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is a current need to develop a split-dose cisplatinum regimen in combination with&#xD;
      pemetrexed with high efficacy, excellent treatment compliance, administration convenience and&#xD;
      the possibility to open up easier outpatient administration of the chemotherapy protocol.&#xD;
      Dosing of cisplatinum at 40 mg/m2 d 1 and day 8 seems to be very effective and useful for&#xD;
      this strategy. The current trial will address this issue within a prospective randomized&#xD;
      phase-II trial. Treatment will be given on day 1 and 8 in the split-dose arm. A comparator&#xD;
      arm of the current three-weekly higher cisplatinum schedule will be added to this study. For&#xD;
      evaluation of this strategy observation of the toxicity/efficacy ratio within this trial will&#xD;
      be of major importance. Efficacy will be analyzed by objective response rate, symptom control&#xD;
      and life-quality. Toxicity will be looked at with treatment toxicity, treatment compliance&#xD;
      and adherence to protocol.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">April 2015</completion_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <condition>NSCLC</condition>
  <arm_group>
    <arm_group_label>Cis (D1) + Pem (D1)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cisplatinum 75 mg/m2 d 1 Pemetrexed 500 mg/m2 d 1 q d 21</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CIS (D1+8) + Pem (D!)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cisplatinum 40 mg/m2 d 1 + d 8 Pemetrexed 500 mg/m2 d 1 q d 21</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatinum</intervention_name>
    <arm_group_label>CIS (D1+8) + Pem (D!)</arm_group_label>
    <arm_group_label>Cis (D1) + Pem (D1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <arm_group_label>CIS (D1+8) + Pem (D!)</arm_group_label>
    <arm_group_label>Cis (D1) + Pem (D1)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients are eligible to be included in the study only if they meet all of the&#xD;
             following criteria:&#xD;
&#xD;
               1. Histologically or cytologically confirmed diagnosis of non-squamous-cell&#xD;
                  non-small cell lung cancer (NSCLC) Stage IV (American Joint Committee on Cancer&#xD;
                  Staging Criteria [AJCC], Version 7, 2009)&#xD;
&#xD;
               2. No prior systemic chemotherapy for lung cancer&#xD;
&#xD;
               3. At least one unidimensionally measurable lesion meeting Response Evaluation&#xD;
                  Criteria in Solid Tumours (RECIST; version 1.1, Eisenhauer et al. 2009), longest&#xD;
                  diameter ≥10 mm with computed tomography (CT) scan [CT scan slice thickness no&#xD;
                  greater than 5 mm] , or ≥ 20 mm with chest x-ray. Positron emission tomography&#xD;
                  (PET) scans and ultrasounds should not be used.&#xD;
&#xD;
               4. ECOG performance status of 0 or 1 (Oken et al. 1982)&#xD;
&#xD;
               5. ≥ 18 years of age &lt; 75 years&#xD;
&#xD;
               6. Adequate organ function,&#xD;
&#xD;
               7. Prior radiation therapy allowed to &lt;25% of the bone marrow (Cristy and Eckerman&#xD;
                  1987). Prior radiation to the whole pelvis is not allowed. Prior radiotherapy&#xD;
                  must be completed at least 4 weeks before study enrollment. Patients must have&#xD;
                  recovered from the acute toxic effects of the treatment prior to study&#xD;
                  enrollment.&#xD;
&#xD;
               8. Patient must understand and sign an informed consent document before the start of&#xD;
                  specific protocol procedures.&#xD;
&#xD;
               9. A pretreatment FFPE tumour biopsy must be available for central biomarker&#xD;
                  analysis. If consented by the patient and clinically feasible, a fresh&#xD;
                  pretreatment biopsy is obtained and submitted for central biomarker analysis.&#xD;
&#xD;
              10. Female patients with childbearing potential must use highly effective methods of&#xD;
                  contraception (combined oral contraceptives, hormon-releasing intrauterine&#xD;
                  contraceptive device, hormonal contraceptive implants, hormonal contraceptive&#xD;
                  injectables) or have sexual intercourse with a vasectomised partner only during&#xD;
                  and for 6 months after the study and their pregnancy test must be negative within&#xD;
                  7 days prior to study enrollment.&#xD;
&#xD;
                  A female subject is considered to be of childbearing potential unless she is age&#xD;
                  ≥ 50 years and naturally amenorrhoeic for ≥ 2 year or unless she is surgically&#xD;
                  sterile.&#xD;
&#xD;
                  Male patients must agree to use condoms during the study and for 6 months after&#xD;
                  the study if their partner is of childbearing potential and does not use highly&#xD;
                  effective method of contraception.&#xD;
&#xD;
              11. Estimated life expectancy of 12 weeks&#xD;
&#xD;
              12. Patient compliance and geographic proximity that allow adequate follow up.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients will be excluded from the study if they meet any of the following criteria:&#xD;
&#xD;
               1. Active participation in other clinical studies or treatment with any experimental&#xD;
                  drug within 30 days prior to study enrollment or during study participation.&#xD;
&#xD;
               2. Patients with known somatic activating mutations of EGFR, as these patients&#xD;
                  should be offered EGFR- tyrosine kinase inhibitor (EGFR-TKI) treatment as&#xD;
                  first-line therapy. Detection of EGFR mutations and additional somatic mutations&#xD;
                  with relation to treatment will be performed centrally at the&#xD;
                  Universitätsklinikum Essen. In case immediate treatment initiation is required&#xD;
                  for medical reasons (such as superior vena cava syndrome, severely symptomatic&#xD;
                  disease) patients may be enrolled before results from EGFR testing are available.&#xD;
                  As EGFR-TKI treatment is equally effective in second-line therapy, such patients&#xD;
                  may remain on study treatment if a clinical benefit is derived.&#xD;
&#xD;
               3. Peripheral neuropathy of ³CTCAE Grade 1&#xD;
&#xD;
               4. Inability to comply with protocol or study procedures&#xD;
&#xD;
               5. A serious concomitant systemic disorder that, in the opinion of the investigator,&#xD;
                  would compromise the patient's ability to complete the study.&#xD;
&#xD;
               6. A serious cardiac condition, such as myocardial infarction within 6 months prior&#xD;
                  to study enrollment, symptomatic coronary artery disease, cardiac arrhythmia, or&#xD;
                  other heart disease, as defined by the New York Heart Association Class III or IV&#xD;
                  (functional capacity)&#xD;
&#xD;
               7. Second primary malignancy that is clinically detectable at the time of&#xD;
                  consideration for study enrollment&#xD;
&#xD;
               8. Documented brain metastases unless the patient has completed successful local&#xD;
                  therapy for central nervous system metastases and has been off of corticosteroids&#xD;
                  for at least 4 weeks before enrollment. Brain imaging is required in symptomatic&#xD;
                  patients to rule out brain metastases,but is not required in asymptomatic&#xD;
                  patients&#xD;
&#xD;
               9. The effect of third space fluid, such as pleural effusion and ascites, on&#xD;
                  pemetrexed is unknown. In patients with clinically significant third space fluid,&#xD;
                  consideration should be given to draining the effusion prior to pemetrexed&#xD;
                  administration.&#xD;
&#xD;
              10. Significant weight loss (that is 10%) over the previous 6 weeks before study&#xD;
                  entry&#xD;
&#xD;
              11. Significant hearing function impairment, especially high-frequency hearing&#xD;
                  function impairment&#xD;
&#xD;
              12. Any active or uncontrolled infection&#xD;
&#xD;
              13. Concurrent administration of any other antitumour therapy&#xD;
&#xD;
              14. Inability to interrupt aspirin or other nonsteroidal anti-inflammatory agents,&#xD;
                  other than an aspirin dose &lt;1.3 grams per day, for a 5-day period (8-day period&#xD;
                  for long-acting agents, such as piroxicam)&#xD;
&#xD;
              15. Inability or unwillingness to take folic acid or vitamin B12 supplementation&#xD;
&#xD;
              16. Inability to take corticosteroids&#xD;
&#xD;
              17. Hypersensitivity to cisplatinum or to any other platinum compound&#xD;
&#xD;
              18. Hypersensitivity to pemetrexed or to any of the excipients of ALIMTA®&#xD;
&#xD;
              19. Pregnant or breast-feeding patient&#xD;
&#xD;
              20. Yellow fever vaccination within the 30 days previous to study entry.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wilfried Eberhardt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universital hospital essen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wilfried Eberhardt, MD</last_name>
    <phone>00492017232011</phone>
    <email>wilfried.eberhardt@uk-essen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mathias Hoiczyk</last_name>
    <phone>00492017232011</phone>
    <email>mathias.hoiczyk@uk-essen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University hospital essen</name>
      <address>
        <city>Essen</city>
        <state>Northrhine westphalia</state>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diana Cortes-Incio</last_name>
      <phone>02017232011</phone>
      <email>diana.cortez-incio@uk-essen.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <study_first_submitted>December 3, 2012</study_first_submitted>
  <study_first_submitted_qc>December 4, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2012</study_first_posted>
  <last_update_submitted>December 4, 2012</last_update_submitted>
  <last_update_submitted_qc>December 4, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 5, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universität Duisburg-Essen</investigator_affiliation>
    <investigator_full_name>Mathias Hoiczyk</investigator_full_name>
    <investigator_title>Physician</investigator_title>
  </responsible_party>
  <keyword>NSCLC; split dose Cisplatinum; Pemetrexed</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pemetrexed</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

